Literature DB >> 28387952

Work productivity in rhinitis using cell phones: The MASK pilot study.

J Bousquet1,2,3, M Bewick4, S Arnavielhe5, E Mathieu-Dupas5, R Murray6, A Bedbrook1, D P Caimmi7,8, O Vandenplas9, P W Hellings10, C Bachert11, J M Anto12, K C Bergmann13, C Bindslev-Jensen14, S Bosnic-Anticevich15, J Bouchard16,17, G W Canonica18, N H Chavannes19, A A Cruz20,21, R Dahl20,21, P Demoly8, G De Vries22, P Devillier23, A Fink-Wagner24, W J Fokkens25, J Fonseca26,27, N A Guldemond28, T Haahtela29, B Hellqvist-Dahl30, J Just31,32, T Keil33,34, L Klimek35, M L Kowalski36,37, P Kuna38, V Kvedariene39, D Laune5, D Larenas-Linnemann40, J Mullol41, A M Pereira42,43,44, P Carreiro-Martins45,46, E Melén47, M Morais-Almeida48, L Nogueira-Silva49, R E O'Hehir50,51, N G Papadopoulos52,53, G Passalacqua54, F Portejoie1, D Price55,56,57, D Ryan58, B Samolinski59, A Sheikh60, F E R Simons61, O Spranger24, A Todo Bom62, P V Tomazic63, M Triggiani64, A Valero65, E Valovirta66,67, A Valiulis68,69, M van Eerd22, M Wickman47, I Young70, T Zuberbier13.   

Abstract

Allergic rhinitis often impairs social life and performance. The aim of this cross-sectional study was to use cell phone data to assess the impact on work productivity of uncontrolled rhinitis assessed by visual analogue scale (VAS). A mobile phone app (Allergy Diary, Google Play Store and Apple App Store) collects data from daily visual analogue scales (VAS) for overall allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as work (VAS-work). A combined nasal-ocular score is calculated. The Allergy Diary is available in 21 countries. The app includes the Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI:AS) in six EU countries. All consecutive users who completed the VAS-work from 1 June to 31 October 2016 were included in the study. A total of 1136 users filled in 5818 days of VAS-work. Symptoms of allergic rhinitis were controlled (VAS-global <20) in approximately 60% of the days. In users with uncontrolled rhinitis, approximately 90% had some work impairment and over 50% had severe work impairment (VAS-work >50). There was a significant correlation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001, Spearman's rank test). In 144 users, there was a significant correlation between VAS-work and WPAI:AS (Rho=0.53, P<0.0001). This pilot study provides not only proof-of-concept data on the work impairment collected with the app but also data on the app itself, especially the distribution of responses for the VAS. This supports the interpretation that persons with rhinitis report both the presence and the absence of symptoms.
© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  Allergic Rhinitis and its Impact on Asthma; WPAIA:AS; app; rhinitis; work productivity

Mesh:

Year:  2017        PMID: 28387952     DOI: 10.1111/all.13177

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  17 in total

1.  Social Media and Allergy.

Authors:  Ves Dimov; Alexei Gonzalez-Estrada; Frank Eidelman
Journal:  Curr Allergy Asthma Rep       Date:  2018-11-14       Impact factor: 4.806

Review 2.  Digital transformation of health and care to sustain Planetary Health: The MASK proof-of-concept for airway diseases-POLLAR symposium under the auspices of Finland's Presidency of the EU, 2019 and MACVIA-France, Global Alliance against Chronic Respiratory Diseases (GARD, WH0) demonstration project, Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

Authors:  Jean Bousquet; Josep M Anto; Tari Haahtela; Pekka Jousilahti; Marina Erhola; Xavier Basagaña; Wienczyslawa Czarlewski; Mikaëla Odemyr; Susanna Palkonen; Mikael Sofiev; César Velasco; Anna Bedbrook; Rodrigo Delgado; Rostislav Kouznetsov; Mika Mäkelä; Yuliia Palamarchuk; Kimmo Saarinen; Erja Tommila; Erkka Valovirta; Tuula Vasankari; Torsten Zuberbier; Isabella Annesi-Maesano; Samuel Benveniste; Eve Mathieu-Dupas; Jean-Louis Pépin; Robert Picard; Stéphane Zeng; Julia Ayache; Nuria Calves Venturos; Yann Micheli; Ingrid Jullian-Desayes; Daniel Laune
Journal:  Clin Transl Allergy       Date:  2020-06-19       Impact factor: 5.871

Review 3.  Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management.

Authors:  C Bachert; J Bousquet; P Hellings
Journal:  Clin Transl Allergy       Date:  2018-06-25       Impact factor: 5.871

Review 4.  Highlights and recent developments in airway diseases in EAACI journals (2017).

Authors:  J Bousquet; C A Akdis; C Grattan; P A Eigenmann; K Hoffmann-Sommergruber; P W Hellings; I Agache
Journal:  Clin Transl Allergy       Date:  2018-11-27       Impact factor: 5.871

Review 5.  POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project.

Authors:  Jean Bousquet; Josep M Anto; Isabella Annesi-Maesano; Toni Dedeu; Eve Dupas; Jean-Louis Pépin; Landry Stephane Zeng Eyindanga; Sylvie Arnavielhe; Julia Ayache; Xavier Basagana; Samuel Benveniste; Nuria Calves Venturos; Hing Kin Chan; Mehdi Cheraitia; Yves Dauvilliers; Judith Garcia-Aymerich; Ingrid Jullian-Desayes; Chitra Dinesh; Daniel Laune; Jade Lu Dac; Ismael Nujurally; Giovanni Pau; Robert Picard; Xavier Rodo; Renaud Tamisier; Michael Bewick; Nils E Billo; Wienczyslawa Czarlewski; Joao Fonseca; Ludger Klimek; Oliver Pfaar; Jean-Marc Bourez
Journal:  Clin Transl Allergy       Date:  2018-09-17       Impact factor: 5.871

Review 6.  Clinical trials in allergen immunotherapy: current concepts and future needs.

Authors:  O Pfaar; M Alvaro; V Cardona; E Hamelmann; R Mösges; J Kleine-Tebbe
Journal:  Allergy       Date:  2018-04-16       Impact factor: 13.146

7.  Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study.

Authors:  D Samreth; S Arnavielhe; F Ingenrieth; A Bedbrook; G L Onorato; R Murray; R Almeida; M A Mizani; J Fonseca; E Costa; J Malva; M Morais-Almeida; A M Pereira; A Todo-Bom; E Menditto; C Stellato; M T Ventura; D Larenas-Linnemann; J-M Fuentes-Pérez; Y R Huerta-Villalobos; A A Cruz; R Stelmach; J da Silva; R Emuzyte; V Kvedariene; A Valiulis; I Annesi-Maesano; I Bosse; P Demoly; P Devillier; J F Fontaine; P Kuna; B Samolinski; L Klimek; R Mösges; O Pfaar; S Shamai; M Bewick; D Ryan; A Sheikh; J M Anto; V Cardona; J Mullol; A Valero; N H Chavannes; W J Fokkens; S Reitsma; R E Roller-Wirnsberger; P V Tomazic; T Haahtela; S Toppila-Salmi; E Valovirta; M Makris; N G Papadopoulos; E P Prokopakis; F Psarros; B Gemicioğlu; A Yorgancioglu; C Bindslev-Jensen; E Eller; I Kull; M Wickman; C Bachert; P W Hellings; B Pugin; S Bosnic-Anticevich; R E O'Hehir; V Kolek; M Sova; K Wehner; G De Vries; M van Eerd; D Laune; J Wittmann; J Bousquet; P Poncelet
Journal:  World Allergy Organ J       Date:  2018-07-16       Impact factor: 4.084

8.  Economic Burden of the Inadequate Management of Allergic Rhinitis and Urticaria in Asian Countries Based on the GA²LEN Model.

Authors:  Kanokvalai Kulthanan; Supinda Chusakul; Marysia Tiongco Recto; Ma Teresita Gabriel; Derrick Chen Wee Aw; Narayanan Prepageran; Alson Wong; Jern Lin Leong; Henry Foong; Vo Thanh Quang; Torsten Zuberbier
Journal:  Allergy Asthma Immunol Res       Date:  2018-07       Impact factor: 5.764

Review 9.  CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report.

Authors:  J Bousquet; G L Onorato; C Bachert; M Barbolini; A Bedbrook; L Bjermer; J Correia de Sousa; N H Chavannes; A A Cruz; E De Manuel Keenoy; P Devillier; J Fonseca; S Hun; T Kostka; P W Hellings; M Illario; J C Ivancevich; D Larenas-Linnemann; J Millot-Keurinck; D Ryan; B Samolinski; A Sheikh; A Yorgancioglu; I Agache; S Arnavielhe; M Bewick; I Annesi-Maesano; J M Anto; K C Bergmann; C Bindslev-Jensen; S Bosnic-Anticevich; J Bouchard; D P Caimmi; P Camargos; G W Canonica; V Cardona; A M Carriazo; C Cingi; E Colgan; A Custovic; R Dahl; P Demoly; G De Vries; W J Fokkens; J F Fontaine; B Gemicioğlu; N Guldemond; Z Gutter; T Haahtela; B Hellqvist-Dahl; E Jares; G Joos; J Just; N Khaltaev; T Keil; L Klimek; M L Kowalski; I Kull; P Kuna; V Kvedariene; D Laune; R Louis; A Magnan; J Malva; E Mathieu-Dupas; E Melén; E Menditto; M Morais-Almeida; R Mösges; J Mullol; R Murray; H Neffen; R O'Hehir; S Palkonen; N G Papadopoulos; G Passalacqua; J L Pépin; F Portejoie; D Price; B Pugin; F Raciborski; F E R Simons; M Sova; O Spranger; C Stellato; A Todo Bom; P V Tomazic; M Triggiani; A Valero; E Valovirta; O VandenPlas; A Valiulis; M van Eerd; M T Ventura; M Wickman; I Young; T Zuberbier; A Zurkuhlen; A Senn
Journal:  Clin Transl Allergy       Date:  2017-10-23       Impact factor: 5.871

Review 10.  MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence.

Authors:  J Bousquet; S Arnavielhe; A Bedbrook; M Bewick; D Laune; E Mathieu-Dupas; R Murray; G L Onorato; J L Pépin; R Picard; F Portejoie; E Costa; J Fonseca; O Lourenço; M Morais-Almeida; A Todo-Bom; A A Cruz; J da Silva; F S Serpa; M Illario; E Menditto; L Cecchi; R Monti; L Napoli; M T Ventura; G De Feo; D Larenas-Linnemann; M Fuentes Perez; Y R Huerta Villabolos; D Rivero-Yeverino; E Rodriguez-Zagal; F Amat; I Annesi-Maesano; I Bosse; P Demoly; P Devillier; J F Fontaine; J Just; T P Kuna; B Samolinski; A Valiulis; R Emuzyte; V Kvedariene; D Ryan; A Sheikh; P Schmidt-Grendelmeier; L Klimek; O Pfaar; K C Bergmann; R Mösges; T Zuberbier; R E Roller-Wirnsberger; P Tomazic; W J Fokkens; N H Chavannes; S Reitsma; J M Anto; V Cardona; T Dedeu; J Mullol; T Haahtela; J Salimäki; S Toppila-Salmi; E Valovirta; B Gemicioğlu; A Yorgancioglu; N Papadopoulos; E P Prokopakis; S Bosnic-Anticevich; R O'Hehir; J C Ivancevich; H Neffen; E Zernotti; I Kull; E Melen; M Wickman; C Bachert; P Hellings; S Palkonen; C Bindslev-Jensen; E Eller; S Waserman; M Sova; G De Vries; M van Eerd; I Agache; T Casale; M Dykewickz; R N Naclerio; Y Okamoto; D V Wallace
Journal:  Clin Transl Allergy       Date:  2018-10-25       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.